CVS Health Updates EPS Guidance and Operational Plansby Mark Eisenberg 08.08.2024CVS Health revises full-year EPS guidance to $6.40-$6.55 and plans significant operational improvements to drive future growth.
AppLovin Shares Drop 7% Despite Beating Earnings Estimatesby Mark Eisenberg 08.08.2024AppLovin reported better-than-expected Q2 earnings and strong Q3 guidance, yet shares fell 7% in after-hours trading.
Zest AI Launches Fraud Detection Solution to Combat Loan Fraudby Lilu Anderson 08.08.2024Zest AI's new tool uses AI to tackle the 69% rise in loan fraud cases. This solution enhances fraud detection ...
Global Medical REIT Reports Q2 Net Loss Amid Acquisition Movesby Mark Eisenberg 08.08.2024Global Medical REIT reports $3.1M net loss for Q2 2024. Key highlights include acquisitions and high portfolio occupancy despite challenges.
Disney and Super Micro Stocks Drop After Earnings Missby Mark Eisenberg 08.08.2024Disney and Super Micro's earnings failed investor expectations, causing stock drops. Warner Bros. Discovery's results are awaited.
Wolverine World Wide Exceeds Q2 Expectations Despite Revenue Dipby Mark Eisenberg 08.08.2024Wolverine World Wide beats Q2 earnings estimates with $425.2 million revenue, despite a 17.4% YoY decline.
Southwest Gas Holdings Raises 2024 Net Income Guidance by $5 Millionby Mark Eisenberg 07.08.2024Southwest Gas Holdings Inc.'s Q2 earnings call highlights increased net income guidance, strategic initiatives, and strong financial position.
BTB REIT Q2 Results: Mixed Outcomes Amid Market Fluctuationsby Mark Eisenberg 07.08.2024BTB REIT reports mixed Q2 results with record occupancy but declining FFO per unit. Financial strategies and market shifts impact ...
Crexendo’s Q2 2024 Results Showcase Significant Growthby Mark Eisenberg 07.08.2024Crexendo reports a 16% YoY revenue increase and a 220% rise in net income for Q2 2024, driven by strong ...
Veracyte Reports Strong Q2 Growth with 27% Revenue Increaseby Mark Eisenberg 07.08.2024Veracyte's Q2 revenue surged 27% to $114.4M, fueled by strong demand for genomic tests. Full-year guidance raised to $432M-$438M.